NRX Pharmaceuticals (NRXP) Net Income towards Common Stockholders (QoQ) (2018 - 2026)
NRX Pharmaceuticals (NRXP) Net Income towards Common Stockholders (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | NRX Pharmaceuticals | 117.34 Mn | 110.64 Mn | 437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.58% |
| Dec 31, 2025 | -9.71% |
| Sep 30, 2025 | -12.96% |
| Jun 30, 2025 | 2.99% |
| Mar 31, 2025 | -58.28% |
| Dec 31, 2024 | 19.58% |
| Sep 30, 2024 | 57.13% |
| Jun 30, 2024 | -11.00% |
| Mar 31, 2024 | -43.81% |
| Dec 31, 2023 | 28.71% |
| Sep 30, 2023 | 23.49% |
| Jun 30, 2023 | -103.91% |
| Mar 31, 2023 | 61.26% |
| Dec 31, 2022 | -12.75% |
| Sep 30, 2022 | -30.09% |
| Jun 30, 2022 | 58.22% |
| Mar 31, 2022 | 45.04% |
| Dec 31, 2021 | 17.93% |
| Sep 30, 2021 | 85.52% |
| Jun 30, 2021 | -28,537.67% |